Monsanto Roundup Lawsuit

Wednesday, January 07, 2009

Dr. Graham J. Emslie is 'At It Again'

Remember the infamous Paxil 329 study?

It seems some of those involved in protecting SmithKline Beecham are at it again.

One would have thought lessons would have been learned... but then again we are dealing with greed here and it seems Dr. Graham J. Emslie is once again playing a major role.

Emslie was the lead author for Prozac Study X065, his published paper metioned nothing about suicide ideation. That was false.

Emslie was contracted by GlaxoSmithKline as an investigator in a study examining the effects of Paxil [Seroxat] on child/adolescent depression. He was fully aware that Paxil was no more effective than a placebo. When asked about this he replied somewhat astonishingly, "I couldn’t talk about it because it was proprietary."

Graham Emslie is a professor of psychiatry at the University of Texas Southwestern Medical Center, who has helped conduct several trials for drug companies, counted nine trials of Prozac, Paxil, Zoloft and Celexa in depressed children.

Now here this - Oh yea, oh yea...

Children With Milder Depression May Get Little Help From Antidepressant Drugs

Unbeleiveable isn't it?

Surely some sort of prank?

Not so.

Jeffrey A. Bridge, PhD, of Nationwide Children's Hospital in Columbus, Ohio, and colleagues found that kids enrolled in multicenter clinical trials were much more likely to respond to placebo than were kids in smaller trials. They also found that kids in larger trials tended to have less severe depression than kids in smaller trials.

This, they suggest, may mean that antidepressants are most helpful to kids with at least moderately severe depression.

And who is on hand to 'big up' this claim?

"Doctors who treat children for depression should pay close attention to this finding", suggests an editorial by Graham J. Emslie, MD, of the University of Texas Southwestern Medical Center in Dallas.

Not only that, Emslie continues with:

"The study "emphasizes the importance of a careful and extended evaluation prior to initiating medication to make sure that the depression is of sufficient severity to warrant medication treatment."

As if that wasn't enough, Emslie continued to sell his soul with:

"The large placebo effect seen in these studies does not mean there's no such thing as child depression -- nor does it mean that these children don't need "vigorous treatment."

Vigorous treatment?

I've news for Emslie: CHILDREN AND ADULTS ARE DYING AS A RESULT OF SSRIS

His biog reads:

Dr. Emslies research foci are in the areas of conducting efficacy and effectiveness trials with medications and psychotherapy for children and adolescents with depression, anxiety disorders, and attention-deficit disorder.

The Bridge study was funded by a grant from the National Institute of Mental Health. Bridge and one of his co-authors have presented at a conference supported by pharmaceutical companies; that co-author has also participated in drug company-sponsored forums. Emslie receives research support from and is a consultant for several drug companies



Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
Post a Comment